IGMS vs. AVBP, AVTE, PHAT, CDMO, CALT, APLT, ATXS, STOK, GHRS, and OLMA
Should you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include ArriVent BioPharma (AVBP), Aerovate Therapeutics (AVTE), Phathom Pharmaceuticals (PHAT), Avid Bioservices (CDMO), Calliditas Therapeutics AB (publ) (CALT), Applied Therapeutics (APLT), Astria Therapeutics (ATXS), Stoke Therapeutics (STOK), GH Research (GHRS), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical preparations" industry.
IGM Biosciences (NASDAQ:IGMS) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.
ArriVent BioPharma has a net margin of 0.00% compared to IGM Biosciences' net margin of -11,255.25%. ArriVent BioPharma's return on equity of 0.00% beat IGM Biosciences' return on equity.
In the previous week, IGM Biosciences and IGM Biosciences both had 12 articles in the media. ArriVent BioPharma's average media sentiment score of 1.23 beat IGM Biosciences' score of 0.38 indicating that ArriVent BioPharma is being referred to more favorably in the news media.
IGM Biosciences presently has a consensus target price of $17.89, suggesting a potential upside of 88.50%. ArriVent BioPharma has a consensus target price of $29.25, suggesting a potential upside of 52.58%. Given IGM Biosciences' higher possible upside, equities analysts plainly believe IGM Biosciences is more favorable than ArriVent BioPharma.
IGM Biosciences received 56 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 49.22% of users gave IGM Biosciences an outperform vote.
ArriVent BioPharma has lower revenue, but higher earnings than IGM Biosciences.
42.8% of IGM Biosciences shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 56.9% of IGM Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
ArriVent BioPharma beats IGM Biosciences on 7 of the 12 factors compared between the two stocks.
Get IGM Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IGM Biosciences Competitors List
Related Companies and Tools
